Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A systematic review of the safety and efficacy of currently used treatment modalities in the treatment of patients with PIK3CA-related overgrowth spectrum.

Journal of vascular surgery. Venous and lymphatic disorders - 1 Mar 2022

Bernhard Sarah M, Adam Luise, Atef Hady, Häberli Dario, Bramer Wichor M, Minder Beatrice, Döring Yvonne, Laine Jessica E, Muka Taulant, Rössler Jochen, Baumgartner Iris

Abstract excerpt

BACKGROUND: PIK3CA (activating mutations of the p110α subunit of phosphatidylinositol 3-kinases)-related overgrowth spectrums (PROS) include a variety of clinical presentations that are associated with hypertrophy of different parts of the body. We performed a systematic literature review to assess the current treatment options and their efficacy and safety for PROS. METHODS: A literature search was performed in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases
Share to Genetic Predisposition to Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hypertrophy

Share to Molecular Targeted Therapy

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Signal Transduction

Share to Syndrome

Share to Treatment Outcome

Source

Identifiers

PMID: 34358672
DOI: 10.1016/j.jvsv.2021.07.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A systematic review of the safety and efficacy of currently used treatment modalities in the treatment of patients with PIK3CA-related overgrowth spectrum.PMID 34358672Read ↗

Updates on Diagnosis and Treatment of PIK3CA-Related Overgrowth Spectrum.Semantic proximity Read ↗

Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS).Semantic proximity Read ↗

PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.Semantic proximity Read ↗

PIK3CA-Related Overgrowth Spectrum From Diagnosis to Targeted Therapy: A Case of CLOVES Syndrome Treated With AlpelisibSemantic proximity Read ↗

Clinical and Genetic Analyses and Treatment Experiences of Patients with Lateralized OvergrowthSemantic proximity Read ↗

Alpelisib to treat CLOVES syndrome, a member of the PIK3CA-related overgrowth syndrome spectrumSemantic proximity Read ↗

[PIK3CA-related overgrowth spectrum (PROS): new insight in known diseases].Semantic proximity Read ↗

Safety findings from the phase 1/2 MOSAIC study of miransertib for patients with PIK3CA-related overgrowth spectrum or Proteus syndromeSemantic proximity Read ↗

Alpelisib to treat CLOVES syndrome, a member of the PIK3CA-related overgrowth syndrome spectrum.Semantic proximity Read ↗

Clinical Experience with the AKT1 Inhibitor Miransertib in two Children with PIK3CA-related overgrowth syndromeSemantic proximity Read ↗

PIK3CA-related overgrowth spectrum: animal model and drug discovery.Semantic proximity Read ↗

Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.